OncoSil Medical Limited (ASX:OSL)
Australia
· Delayed Price · Currency is AUD 0.625
-0.005 (-0.79%)
Mar 6, 2026, 3:25 PM AEST
OncoSil Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Operating Revenue | 1.49 | 1.17 | 0.52 | 0.37 | 0.23 | 0.21 | Upgrade
|
| Other Revenue | 2.23 | 0.36 | 1.05 | 1.1 | 0.83 | 1.09 | Upgrade
|
| Revenue | 3.72 | 1.54 | 1.57 | 1.47 | 1.06 | 1.3 | Upgrade
|
| Revenue Growth (YoY) | 95.02% | -1.92% | 6.68% | 38.00% | -18.09% | -53.02% | Upgrade
|
| Cost of Revenue | 2.65 | 2.25 | 1.51 | 1.59 | 0.97 | 0.96 | Upgrade
|
| Gross Profit | 1.07 | -0.72 | 0.06 | -0.12 | 0.09 | 0.34 | Upgrade
|
| Selling, General & Admin | 9.06 | 10.16 | 9.05 | 8.36 | 8.29 | 7.99 | Upgrade
|
| Research & Development | 5.21 | 4.21 | 2.99 | 2.85 | 2.38 | 2.89 | Upgrade
|
| Operating Expenses | 14.06 | 14.37 | 12.04 | 11.21 | 10.67 | 10.88 | Upgrade
|
| Operating Income | -12.98 | -15.09 | -11.98 | -11.34 | -10.58 | -10.54 | Upgrade
|
| Interest Expense | -0.02 | -0 | -0 | -0.01 | -0.02 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.1 | 0.09 | 0.07 | 0.06 | 0.01 | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.1 | 0.01 | -0.06 | -0.14 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | -12.92 | -15.1 | -11.91 | -11.34 | -10.73 | -10.58 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.15 | Upgrade
|
| Pretax Income | -12.92 | -15.1 | -11.91 | -11.34 | -10.73 | -10.43 | Upgrade
|
| Net Income | -12.92 | -15.1 | -11.91 | -11.34 | -10.73 | -10.43 | Upgrade
|
| Net Income to Common | -12.92 | -15.1 | -11.91 | -11.34 | -10.73 | -10.43 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 11 | 6 | 3 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 11 | 6 | 3 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 89.96% | 97.77% | 95.67% | 39.32% | -0.89% | 24.68% | Upgrade
|
| EPS (Basic) | -0.85 | -1.38 | -2.16 | -4.02 | -5.29 | -5.10 | Upgrade
|
| EPS (Diluted) | -0.85 | -1.38 | -2.16 | -4.02 | -5.29 | -5.12 | Upgrade
|
| Free Cash Flow | -12.91 | -12.08 | -11.02 | -11.37 | -10.12 | -8.87 | Upgrade
|
| Free Cash Flow Per Share | -0.85 | -1.10 | -2.00 | -4.03 | -4.99 | -4.34 | Upgrade
|
| Gross Margin | 28.83% | -46.79% | 3.55% | -8.27% | 8.55% | 25.98% | Upgrade
|
| Operating Margin | -348.58% | -982.80% | -765.58% | -772.48% | -994.72% | -811.96% | Upgrade
|
| Profit Margin | -346.80% | -983.53% | -761.07% | -772.98% | -1008.73% | -803.61% | Upgrade
|
| Free Cash Flow Margin | -346.72% | -786.66% | -704.07% | -775.06% | -951.30% | -683.14% | Upgrade
|
| EBITDA | -12.98 | -15.08 | -11.98 | -11.32 | -10.55 | -10.51 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | Upgrade
|
| EBIT | -12.98 | -15.09 | -11.98 | -11.34 | -10.58 | -10.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.